TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Simulated Diabetes Training for Resident Physicians
Brief Summary: The objective of this translational research is to study the effect of implementing an innovative simulated diabetes learning intervention within primary care residency programs. The intervention uses cognitive behavioral learning theory to provide goal-directed feedback to residents after every encounter over a series of virtual patient-physician encounters. Formulas derived from pharmacokinetic data and the experience of clinical experts model simulated physiologic responses to drug changes, health behaviors, and adherence factors. The online intervention is economical, sustainable, and addresses a number of current obstacles to outpatient diabetes training in primary care residency programs.

In this group trial, we randomly assign about 20 primary care residency programs with up to 700 residents total to either an (a) Early learning program group or (b) Delayed learning program group. We will assess the ability of residents to achieve evidence-based diabetes clinical goals and avoid potential medical safety issues for glycemia, blood pressure, and lipids on simulated assessment cases. Secondary analyses will evaluate the actual use of the tool by residents, direct costs of the program, and resident satisfaction.


Options:
A: Arm Label: Primary Care-Occupational Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Primary Care-Occupational Therapy | Arm Label: Enhanced Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Primary Care-Occupational Therapy; Assigned to Arm(s): Primary Care-Occupational Therapy | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Early SimCare Diabetes Group; Type: EXPERIMENTAL; Interventions: Other: Early SimCare Diabetes Group | Arm Label: Delayed SimCare Diabetes Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Delayed SimCare Diabetes Group | Intervention Type: OTHER; Name: Early SimCare Diabetes Group; Assigned to Arm(s): Early SimCare Diabetes Group | Intervention Type: OTHER; Name: Delayed SimCare Diabetes Group; Assigned to Arm(s): Delayed SimCare Diabetes Group
C: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Osteoarthritis is a common disease. The core treatment is often patient education. The aim of this study is therefore to study the effect of a patient education programme for patients with osteoarthritis in primary health care.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Behavioral Intervention for OA | Arm Label: Provider Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Provider Intervention for OA | Arm Label: Patient and Provider Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: Combined Patient and Provider Interventions for OA | Intervention Type: BEHAVIORAL; Name: Patient Behavioral Intervention for OA; Assigned to Arm(s): Patient Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Provider Intervention for OA; Assigned to Arm(s): Provider Intervention | Intervention Type: BEHAVIORAL; Name: Combined Patient and Provider Interventions for OA; Assigned to Arm(s): Patient and Provider Interventions
B: Arm Label: Patient education; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Patient education and supervised exercise | Arm Label: Patient education and supervised exercise; Type: EXPERIMENTAL; Interventions: Procedure: Patient education and supervised exercise | Intervention Type: PROCEDURE; Name: Patient education and supervised exercise; Assigned to Arm(s): Patient education, Patient education and supervised exercise
C: Arm Label: Patient education programme; Type: EXPERIMENTAL; Interventions: Other: Patient education programme | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient education programme; Assigned to Arm(s): Patient education programme
D: Arm Label: Health Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Arm Label: Usual Medical Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Osteoarthritis Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Self-Management | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): Health Education Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Self-Management; Assigned to Arm(s): Osteoarthritis Self-Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma
Brief Summary: This will be a prospective, open-label, randomized multicenter phase-II study to evaluate progression free survival (PFS) in patients with locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC) receiving Temsirolimus in comparison to Sunitinib.

In most clinical trials in renal cell carcinoma (RCC), clear cell RCC have been included exclusively. There are only some limited data on the efficacy of Temsirolimus or Sunitinib in ncc-RCC showing interesting response rates for both agents. However, randomized clinical trials in this specific patient population have not yet been performed.

In the proposed study a comparison Temsirolimus and Sunitinib is scheduled in first line therapy of ncc-RCC.


Options:
A: Arm Label: Tivozanib hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib hydrochloride | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Tivozanib hydrochloride; Assigned to Arm(s): Tivozanib hydrochloride | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
B: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B
D: Arm Label: Nintedanib (BIBF 1120); Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: sunitinib | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Nintedanib (BIBF 1120) | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): sunitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial
Brief Summary: The purpose of this study is to determine whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed New Onset Diabetes after Transplantation (NODAT).


Options:
A: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
B: Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control
C: Arm Label: immediate registration on islet graft list; Type: EXPERIMENTAL; Interventions: Biological: Islet Graft | Arm Label: delayed registration on islet graft list; Type: ACTIVE_COMPARATOR; Interventions: Biological: Islet Graft | Intervention Type: BIOLOGICAL; Name: Islet Graft; Assigned to Arm(s): delayed registration on islet graft list, immediate registration on islet graft list
D: Arm Label: Vildagliptin, 50 mg, peroral; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vildagliptin | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin, 50 mg, peroral

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial
Brief Summary: The purpose of this study is to determine whether monotherapy with Vildagliptin improve glycemic control in kidney transplanted patients with newly diagnosed New Onset Diabetes after Transplantation (NODAT).


Options:
A: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
B: Arm Label: Vildagliptin, 50 mg, peroral; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vildagliptin | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin, 50 mg, peroral
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Maternal Obesity on Tissue Concentrations of Prophylactic Antibiotics During Cesarean Delivery
Brief Summary: The purpose of this study is to determine whether the dose of prophylactic antibiotics at the time of cesarean delivery requires adjustment in obese and overweight patients in order to achieve optimal antimicrobial activity.


Options:
A: Arm Label: Ajust sling; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Arm Label: TVT/TVT-O, polypropylne slings; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Intervention Type: PROCEDURE; Name: Ajust system; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings | Intervention Type: PROCEDURE; Name: TVT/TVT-O; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BMI <30; Type: N/A; Interventions: N/A | Arm Label: BMI 30-39; Type: N/A; Interventions: N/A | Arm Label: BMI >40; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a Suicide Attempt. A Pilot Study.
Brief Summary: Scotland has higher rates of suicide than other parts of the UK, an average rate of 15.1 per 100,000 in Scotland compared to 11.4 for England and Wales. The Scottish Government is committed to reducing suicide by 2013. Choose Life has led to staff in services such as Accident and Emergency (A\&E) receiving recent training in suicide prevention through ASIST and STORM.

Evidence for interventions specific to A\&E setting is limited despite the fact that this is the most likely point of first contact with health services for people at risk of this behaviour. Brief interventions that reduce repetition of self harm have not been particularly effective partly because of poor attendance and lack of focus on comorbidity. We propose to pilot an evaluation of a brief focused intervention, ENGAGE (based on MAnualised Cognitive Therapy,MACT, developed by the investigator (Kate Davidson) and Prof Ulrike Schmidt of the Institute of Psychiatry, London) for those who present at A\&E with a suicide attempt and who have a complex presentation - a combination of substance abuse and or personality disorder, all of which are recognized as high risk factors for suicide. ENGAGE will specifically encourage patients to seek appropriate services to meet their mental health needs. This pilot will allow us to assess the feasibility of a full scale study.


Options:
A: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi
B: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment
C: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A
D: Arm Label: App-Condition; Type: EXPERIMENTAL; Interventions: Device: Monsenso DBT-app and IT monitoring program | Arm Label: Paperdiary-condition; Type: ACTIVE_COMPARATOR; Interventions: Other: Paper diary sheet | Intervention Type: OTHER; Name: Paper diary sheet; Assigned to Arm(s): Paperdiary-condition | Intervention Type: DEVICE; Name: Monsenso DBT-app and IT monitoring program; Assigned to Arm(s): App-Condition

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder
Brief Summary: Patients with bipolar disorder are at increased risk of weight gain, which in turn, increases the risk for somatic disease and non-adherence to maintenance therapy. Therefore, interventions addressing weight gain are expedient for the management of this disorder. The investigators set out to evaluate the effects of a lifestyle intervention on body mass index, cardiovascular, glycemic and metabolic parameters in patients with bipolar disorder under mood stabilizing pharmacological treatment. 50 outpatients with bipolar disorder under mood stabilizing treatment participated in a randomized controlled trial (waiting control group N=24 and multimodal lifestyle intervention N=26). Each experimental group consisted of two cohorts. The intervention lasted five months and consisted of eleven group sessions and weekly fitness training. Body Mass Index (BMI), body weight as well as cardiovascular, glycemic and metabolic parameters were determined as baseline (March and September 2005) and after five (July 2005 and January 2006) and eleven months (January and July 2006).


Options:
A: Arm Label: Lifestyle intervention to increase physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: lifestyle intervention to increase physical activity | Arm Label: waiting control group; Type: NO_INTERVENTION; Interventions: Behavioral: lifestyle intervention to increase physical activity | Intervention Type: BEHAVIORAL; Name: lifestyle intervention to increase physical activity; Assigned to Arm(s): Lifestyle intervention to increase physical activity, waiting control group
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: orally-disintegrating olanzapine | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: regular olanzapine | Intervention Type: DRUG; Name: orally-disintegrating olanzapine; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: regular olanzapine; Assigned to Arm(s): Arm 2
C: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
D: Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal
Brief Summary: The Randomized Evaluation of Decolonization versus Universal Clearance to Eliminate MRSA (REDUCE MRSA) Trial is a cluster randomized trial of the comparative effectiveness of three strategies to prevent methicillin-resistant Staphylococcus aureus (MRSA) in intensive care units. The three strategies to be evaluated are:

* screening on admission followed by isolation of MRSA+ patients
* screening on admission followed by isolation and decolonization of MRSA+ patients
* universal decolonization on admission with no screening. The decolonization regimen involves bathing with chlorhexidine plus intra-nasal application of mupirocin. The main outcome will be MRSA+ clinical cultures.

The study is a partnership between the CDC, the CDC Prevention Epicenters, and the Hospital Corporation of America.


Options:
A: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
B: Arm Label: Arm 1: Usual Care-Active Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2: Targeted Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Arm Label: Arm 3: Universal Decolonization; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine bath and nasal mupirocin | Intervention Type: DRUG; Name: Chlorhexidine bath and nasal mupirocin; Assigned to Arm(s): Arm 2: Targeted Decolonization, Arm 3: Universal Decolonization
C: Arm Label: residual gastric volume; Type: OTHER; Interventions: Procedure: monitoring of residual gastric volume | Arm Label: residual gastric volume not monitored; Type: OTHER; Interventions: Procedure: not monitoring of residual gastric volume | Intervention Type: PROCEDURE; Name: monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume | Intervention Type: PROCEDURE; Name: not monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume not monitored
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine oral care (CHX-Oro), Drug: Selective oropharyngeal decontamination (SOD), Drug: Selective Digestive Decontamination (SDD) | Arm Label: Chlorhexidine oral care (CHX-Oro); Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine oral care (CHX-Oro) | Arm Label: Selective oropharyngeal decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective oropharyngeal decontamination (SOD) | Arm Label: Selective digestive decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective Digestive Decontamination (SDD) | Intervention Type: DRUG; Name: Chlorhexidine oral care (CHX-Oro); Assigned to Arm(s): Chlorhexidine oral care (CHX-Oro), Standard care | Intervention Type: DRUG; Name: Selective oropharyngeal decontamination (SOD); Assigned to Arm(s): Selective oropharyngeal decontamination, Standard care | Intervention Type: DRUG; Name: Selective Digestive Decontamination (SDD); Assigned to Arm(s): Selective digestive decontamination, Standard care

Answer: B